Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 03 2024 - 7:01AM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene
editing company utilizing its novel proprietary ARCUS® platform to
develop in vivo gene editing therapies for sophisticated gene edits
including viral gene elimination, today announced that the Company
will present during a fireside chat at the H.C. Wainwright 5th
Annual Viral Hepatitis Virtual Conference taking place October 8,
2024.
Presentation Details:
Date: October 8, 2024 Time: 11:00AM ET
Format: Fireside Chat Webcast Registration: Link
The presentation will be available on Precision’s website under
the Investors section under Events & Presentations at
investor.precisionbiosciences.com. An archived replay will be
available for approximately 30 days following the event.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company
dedicated to improving life (DTIL) with its novel and proprietary
ARCUS® genome editing platform that differs from other technologies
in the way it cuts, its smaller size, and its simpler structure.
Key capabilities and differentiating characteristics may enable
ARCUS nucleases to drive more intended, defined therapeutic
outcomes. Using ARCUS, the Company’s pipeline is comprised of in
vivo gene editing candidates designed to deliver lasting cures for
the broadest range of genetic and infectious diseases where no
adequate treatments exist. For more information about Precision
BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene
editing therapies for sophisticated gene edits, including gene
insertion (inserting DNA into gene to cause expression/add
function), elimination (removing a genome e.g. viral DNA or mutant
mitochondrial DNA), and excision (removing a large portion of a
defective gene by delivering two ARCUS nucleases in a single
AAV).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241003129609/en/
Investor and Media Contact: Naresh Tanna Vice President
of Investor Relations naresh.tanna@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Dec 2024 to Jan 2025
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Jan 2024 to Jan 2025
